Effient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease

DSLLOGO

ORLANDO, Fla., Nov. 15 /PRNewswire-FirstCall/ — Results from a new study showed patients with type 2 diabetes mellitus who also had coronary artery disease (CAD) and received a 60 mg loading dose and 10 mg maintenance dose of Effient® (prasugrel) achieved significantly greater platelet inhibition compared with a 600 mg loading dose and 150 mg maintenance dose of Plavix® (clopidogrel). These data were presented today at the American Heart Association 2009 Scientific Sessions.

The OPTIMUS-3 study, which evaluated 35 patients with type 2 diabetes who also had CAD and were taking aspirin, showed that within four hours, the level of platelet inhibition as measured using the VerifyNow® P2Y12 Test with a 60 mg loading dose of Effient was higher than observed with a 600 mg loading dose of clopidogrel (89 percent vs. 28 percent inhibition of platelet activation [IPA], respectively; P<0.0001). In addition, one hour after the loading dose, patients who received Effient had 50 percent IPA compared with 13 percent in patients who received clopidogrel. The level of platelet inhibition achieved for each drug at four hours was unchanged over the following 24 hours. A 600 mg loading dose of clopidogrel is not currently approved for use.

read full article: Effient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease
prnewswire.com